KHCM
ICPT

Kettle Hill Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Kettle Hill Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-70,256
Closed -$1.62M – 54
2021
Q1 		$1.62M Buy
+70,256
New +$1.96M 0.31% 39

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Kettle Hill Capital Management's ICPT Position: Q2 2021 in Review

Kettle Hill Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 70,256 shares — an estimated $1.62M sold.

Kettle Hill Capital Management first reported a position in ICPT in Q1 2021 and held it in 1 quarter. The position peaked at $1.62M in Q1 2021. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Kettle Hill Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Kettle Hill Capital Management sold 70,256 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $1.62M.
  • Kettle Hill Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Kettle Hill Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $1.62M in Q1 2021.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Kettle Hill Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.